ABBOTT
ACE-INHIBITOR
ACE-INHIBITOR
ACE-INHIBITOR
ACE-INHIBITOR
ACE-INHIBITOR
AHA MEDICAL/SCIENTIFIC STATEMENT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT CLINICAL TRIAL
ALLHAT ENDPOINT
ALLHAT ENDPOINT
ALLHAT MANUAL
ALLHAT CRITERION
ALLHAT CRITERION
HF ALLHAT CRITERION
ALLHAT DEFINITION
HF ALLHAT DEFINITION
ALLHAT EVENT REPORT
ALLHAT EVENT
ALLHAT FOLLOW-UP FORM
ASTRAZENECA
ASTRAZENECA
AD HOC COMMITTEE
ADDITIONAL INFORMATION
ADDITIONAL INFORMATION
ADDITIONAL INFORMATION
ANTIHYPERTENSIVE
ASTRAZENECA
AVENTI
BRISTOL MYERS SQUIBB
BRISTOL MYERS SQUIBB
BRISTOL MYERS SQUIBB
BRISTOL MYERS SQUIBB
BRD
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
DOXAZOSIN BASELINE CHARACTERISTIC
BASELINE PULSE PRESSURE
BETA-BLOCKER
BIOVAIL
CABG
CABG
CORONARY HEART DISEASE
CHD DEATH
CHD EVENT
CTC
CTC
CTC
CTC PHYSICIAN
CARDIOVASCULAR DISEASE
CASE-FATALITY RATE
CASE-FATALITY
PARTICIPANT CASE-FATALITY
CHLORTHALIDONE
CLASSIFICATION
FUNCTIONAL CAPACITY CLASSIFICATION
CLINICAL USE
COMPARABILITY
BASELINE CHARACTERISTIC COMPARABILITY
COMPETING INTEREST
DSMB
DESCRIPTIVE STATISTICS
DIAGNOSTIC CRITERION
DOXAZOSIN PARTICIPANT
ECG
ECG ABNORMALITY
EJECTION FRACTION REVIEW
ENDPOINT FORM
ENDPOINT
FHHL
FUNCTIONAL CAPACITY
GLAXO SMITHKLINE/SMITHKLINE BEECHAM
HDL LEVEL
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF ASCERTAINMENT
HF CASE
HF CASE
HF CASE
MEET ALLHAT DIAGNOSTIC CRITERION HF CASE
HF DIAGNOSIS
HF DIAGNOSIS
HF DIAGNOSIS
HF DIAGNOSIS
HF DIAGNOSIS
HF DIAGNOSIS
HF EVENT
HF EVENT RATE
HF EVENT
HF EVENT
HF EVENT
HF EVENT
HF HOSPITALIZATION
HF INCIDENCE RATE
HF MEDICATION
HF OUTCOME
HF OUTCOME
HF OUTCOME GROUP
HF OUTCOME STATUS
HF PARTICIPANT
HF PATIENT
HF PATIENT
HF RATE
HF STATUS
HF STATUS
HR
HEART ATTACK TRIAL
HEART FAILURE
HEART FAILURE DIAGNOSIS
DIAGNOSTIC CRITERION HEART FAILURE
JNC VI
JTW
KM
KM
KAPLAN-MEIER METHOD
KING PHARMACEUTICALS/MONARCH
LJH
LEFT VENTRICULAR           HYPERTROPHY
LEFT VENTRICULAR           HYPERTROPHY
LIPID
LOWERING TREATMENT LIPID
LOWERING TREATMENT
MEDICAL MANAGEMENT BASELINE CHARACTERISTIC
CHLORTHALIDONE MEDICAL MANAGEMENT BASELINE CHARACTERISTIC
MONITORING BOARD
NHLBI
NP
NATIONAL COMMITTEE
NATIONAL HEART
NATIONAL HEART
NEW YORK HEART CLASSIFICATION
NEW YORK HEART CLASSIFICATION
FUNCTIONAL CLASS III NEW YORK HEART CLASSIFICATION
FUNCTIONAL CLASS III NEW YORK HEART CLASSIFICATION
NOVARTI
NU-PHARM
OBJECTIVE ASSESSMENT
OPEN-LABEL BETA-BLOCKER USE POST-EVENT
OPEN-LABEL DIURETIC
PHARMACIA/UPJOHN
PHARMACIA/UPJOHN
PHARMACIA/UPJOHN
PHARMACIA/UPJOHN
PULSE PRESSURE
PTCA/STENT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PFIZER
PHARMACIA/UPJOHN
POST-HF EVENT MEDICAL MANAGEMENT
POST-DIAGNOSIS PHARMACOLOGIC MANAGEMENT
PRINCIPAL INVESTIGATOR
RR
RR
RR
RR
RANDOMIZATION
RANDOMIZATION
RISK FACTOR
SEARLE
SHEP
ST-T WAVE CHANGE
SOLVAY
SANKYO
SANKYO
SIXTH REPORT
SOLVAY
STATISTICAL ANALYSIS
STUDY GUIDELINES CAUTION
SUBCOMMITTEE QUALITY CONTROL
SYSTOLIC HYPERTENSION
TREATMENT GROUP DIFFERENCE
TWO-THIRDS
EJECTION FRACTION TWO-THIRDS
UNITED STATE
WCC
ABILITY
ACCEPTED TREATMENT
HF ACCEPTED TREATMENT
ACCURACY
ADDED OPEN-LABEL DRUG
ADEQUACY
AFFILIATION
ALL-CAUSE MORTALITY
ALL-CAUSE MORTALITY
ALPHA-ADRENERGIC BLOCKER
AMBIGUITY
AMLODIPINE
ANGINAL PAIN
ANGIOTENSIN-CONVERTING ENZYME (ACE)-INHIBITOR
ANKLE EDEMA
ANTIHYPERTENSIVE DRUG
ANTIHYPERTENSIVE TREATMENT
PARTICIPANT ANTIHYPERTENSIVE TREATMENT
ANTIHYPERTENSIVE TRIAL
APPROPRIATENES
ASYMPTOMATIC HYPERTENSIVE
ATENOLOL
BASELINE SBP
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
BASELINE CHARACTERISTIC
BASELINE ELIGIBILITY RISK FACTOR
BEATS/MINUTE
BETA-BLOCKER
BETA-BLOCKER
BETA-BLOCKER
BETA-BLOCKER
BETA-BLOCKER
BLINDED DRUG
BLINDED FASHION
BLINDED MEDICATION
BLINDED MEDICATION
BLINDED MEDICATION
BLINDED MEDICATION
BLINDED QUALITY CONTROL EVALUATION
BLINDED REVIEW
CALCIUM-CHANNEL BLOCKER
CARDIAC DISEASE
CARDIOVASCULAR CAUSE
CARDIOVASCULAR DISEASE
CARDIOVASCULAR EVENT
CARDIOVASCULAR RISK FACTOR
CASE-FATALITY RATE
CASE-FATALITY RATE
CATEGORICAL VARIABLE
CATHETERIZATION
CHARACTERIZATION
CLINICAL EVENT CHARACTERIZATION
CHEST X-RAY
CHEST X-RAY CHARACTERISTIC
HF CHEST X-RAY CHARACTERISTIC
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
PRIMARY ENDPOINT CHLORTHALIDONE
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE GROUP
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE PARTICIPANT
CHLORTHALIDONE TREATMENT GROUP
CHLORTHALIDONE TREATMENT GROUP
CHLORTHALIDONE TREATMENT GROUP
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CLEAR-CUT SIGN
CLINICAL CENTER
CLINICAL COURSE
CLINICAL DIAGNOSIS
CLINICAL DIAGNOSIS
CLINICAL EVENT
CLINICAL EVENT
CLINICAL INVESTIGATOR
CLINICAL PICTURE
CLINICAL SITE STAFF
CLINICAL TRIAL
COMPARABILITY
COMPELLING INDICATION
COMPELLING REASON
COMPETING CAUSE
COMPETING CAUSE
COMPETING CAUSE
COMPETING INTEREST
CONFIRMATORY EVENT DOCUMENTATION
CONFIRMATORY EVIDENCE
CONSULTANT FEE
CONTINUOUS VARIABLE
CORONARY ARTERY BYPASS GRAFT
CORONARY ARTERY DISEASE
CORONARY REVASCULARIZATION PROCEDURE
CORONARY REVASCULARIZATION PROCEDURE
CORONARY REVASCULARIZATION PROCEDURE
CORONARY REVASCULARIZATION PROCEDURE
CUMULATIVE EVENT RATE
CURRENT CIGARETTE SMOKING
DEATH CERTIFICATE
DEATH CERTIFICATE
DEATH CERTIFICATE
DESCRIPTIVE INFORMATION
DIAGNOSTIC STANDARD
DIAGNOSTIC VALIDITY
DIASTOLIC HF
DIASTOLIC BLOOD PRESSURE
DIASTOLIC DYSFUNCTION
DIASTOLIC DYSFUNCTION
DISCHARGE SUMMARY
DISCHARGE SUMMARY
DIURETIC
DIURETIC
DIURETIC
DIURETIC
DOCUMENTATION
DOCUMENTATION
DOCUMENTATION
DOCUMENTATION
DOCUMENTATION
DOCUMENTATION
QUALITY CONTROL VALIDATION DOCUMENTATION
DOCUMENTED LUNG DISEASE
DOUBLE-BLIND
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN ARM
DOXAZOSIN ARM
DOXAZOSIN ARM
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN GROUP
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN PARTICIPANT
DOXAZOSIN TREATMENT ARM
ANTIHYPERTENSIVE TRIAL DOXAZOSIN TREATMENT ARM
DOXAZOSIN TREATMENT GROUP
DRUG GROUP
DRUG GROUP
DRUG GROUP
DRUG GROUP
DRUG GROUP
DYSPNEA
DYSPNEA
DYSPNEA
ECHOCARDIOGRAM
ECHOCARDIOGRAM
ECHOCARDIOGRAM
EDEMA
EJECTION FRACTION
EJECTION FRACTION DATA
EJECTION FRACTION DATA
EJECTION FRACTION INFORMATION
EJECTION FRACTION
EJECTION FRACTION
EJECTION FRACTION
EJECTION FRACTION
EJECTION FRACTION
ELIGIBILITY FACTOR
ELIGIBILITY RISK FACTOR
ELIGIBILITY RISK FACTOR
EMERGING DIFFERENCE
ENCOMPASSING CHD DEATH
ENDPOINT FORM
ENDPOINT
EVENT ASCERTAINMENT METHOD
EVENT DOCUMENTATION
EVENT REPORT
EXERTIONAL DYSPNEA
EXPLORATORY INVESTIGATION SUPPORT
EXTREMITY EDEMA
FATAL CHD
FATAL CHD
FATAL HF
FATAL HF
FATAL HF
FATAL HF
FATAL HF REPORT
FATAL CORONARY HEART DISEASE
FATAL EVENT
FINAL WORD
FOLLOW-UP CLINIC VISIT
FUNCTIONAL CLASS III
FUNCTIONAL CLASS III
HEART FAILURE
HEART FAILURE
HIGH-DENSITY LIPOPROTEIN
HIGH-RISK HYPERTENSIVE PARTICIPANT
HOSPITAL DISCHARGE
HOSPITALIZATION
HOSPITALIZATION
HOSPITALIZATION
HF HOSPITALIZATION
HOSPITALIZED HF
HOSPITALIZED HF
HOSPITALIZED HF
HOSPITALIZED HF EVENT
HOSPITALIZED HF EVENT
HOSPITALIZED HF EVENT
HOSPITALIZED HF PARTICIPANT
HOSPITALIZED EVENT
HOSPITALIZED NONFATAL HF
HOSPITALIZED NONFATAL HF EVENT
HOSPITALIZED/FATAL HF
HYPERCHOLESTEROLEMIC PATIENT
IN-HOSPITAL
INCLUDING CHD DEATH
INCLUDING CHD DEATH
INCLUDING NONINVASIVE
INCREASED HF EVENT
INCREASED OCCURRENCE
SECONDARY ENDPOINT INCREASED OCCURRENCE
INCREASED RATE
HR INCREASED RATE
INCREASED RELATIVE RISK
INDEPENDENT REVIEW
INVASIVE TOOL
INVOLVING HOSPITALIZATION
JUGULAR VENOUS DISTENTION
LIPID TRIAL
LISINOPRIL
LOST-TO-FOLLOW-UP
LOWERING LDL CHOLESTEROL
MAJOR RISK FACTOR
DIASTOLIC HF MAJOR RISK FACTOR
MANIFESTATION
HF MANIFESTATION
MARKED LIMITATION
PHYSICAL ACTIVITY MARKED LIMITATION
MAXIMUM DOSE
MEAN PP
MEAN BASELINE PP
MEDICATION ADHERENCE
MEET ALLHAT DIAGNOSTIC CRITERION
MENTIONED EJECTION FRACTION
MM HG
MM HG
MM HG
MM HG
MM HG
MM HG
CHLORTHALIDONE MM HG
MORTALITY RATE
NON-CARDIAC CAUSE
NON-HOSPITALIZED HF
NON-HOSPITALIZED PARTICIPANT
NON-MEDICAL STAFF
NONFATAL MI
NONFATAL MI
NONFATAL MI
NONFATAL MI
NONFATAL MI
NONFATAL MYOCARDIAL INFARCTION
OBJECTIVE MEASURE
OBSERVED INCREASE
OPEN-LABEL ACE-INHIBITOR
OPEN-LABEL DIURETIC
OPEN-LABEL DIURETIC
OPEN-LABEL LIPID-LOWERING COMPONENT
OPEN-LABEL MEDICINE
OPEN-LABEL MEDICINE
OPERATIONAL ASPECT
ORDINARY PHYSICAL ACTIVITY CAUSE
ORTHOPNEA
OTHER ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
OTHER ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
OTHER BETA-BLOCKER
OTHER RISK FACTOR
CHD EVENT OTHER RISK FACTOR
OUTPATIENT REVASCULARIZATION
OUTPATIENT REVASCULARIZATION
PAROXYSMAL NOCTURNAL DYSPNEA
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PARTICIPANT
PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
PERIPHERAL ARTERIAL DISEASE
PERIPHERAL ARTERIAL DISEASE
PHYSICAL ACTIVITY
POST-EVENT USE
OPEN-LABEL DIURETIC POST-EVENT USE
POST-HOSPITALIZATION
POTENTIAL DIFFERENCE
POTENTIAL LIMITATION
PRAVASTATIN
PRE-RANDOMIZATION CORONARY ARTERY BYPASS GRAFT
PRE-TRIAL ANTIHYPERTENSIVE TREATMENT DURATION
PRESCRIBED OPEN-LABEL ACE-INHIBITOR
PRESCRIBED OPEN-LABEL DIURETIC
PRESCRIBED OPEN-LABEL DIURETIC
PRESCRIPTION
OPEN-LABEL MEDICINE PRESCRIPTION
PRIMARY ENDPOINT
PRIMARY ENDPOINT
PRIMARY ENDPOINT
PRIMARY ENDPOINT
PROBABILITY
DOXAZOSIN PROBABILITY
SHOWING BENEFIT DOXAZOSIN PROBABILITY
PROTOCOL-DEFINED SECONDARY CLINICAL OUTCOME
PROTOCOL-REQUIRED DOCUMENTATION
PULMONARY DISEASE
PULMONARY PATHOLOGY
QUALITY CONTROL VALIDATION
QUANTIFYING SYSTOLIC FAILURE
QUANTITATIVE MEASUREMENT
RAISING QUESTION
RANDOMIZATION
RANDOMIZATION ASSIGNMENT
RANDOMIZATION GROUP
RANDOMIZATION VISIT
RECEIVED ACE-INHIBITOR
RECOGNIZED TREATMENT
HF RECOGNIZED TREATMENT
RECOMMENDATION
RECOMMENDATION
REPORTED HF
REPORTED HF EVENT
REPORTED HF EVENT
REPORTED EVENT
RESEARCH GRANT
REVIEWED DISCHARGE SUMMARY
MENTIONED EJECTION FRACTION REVIEWED DISCHARGE SUMMARY
ROUTINE ENDPOINT
SUBCOMMITTEE QUALITY CONTROL ROUTINE ENDPOINT
SECONDARY ENDPOINT
SECONDARY ENDPOINT
SHOWED ADHERENCE
SHOWING BENEFIT
SIDE EFFECT
SOMETIMES-DISCREPANT RESULT
STANDARD NORMAL
STATED SIGN
STATED SYMPTOM
STUDY CRITERION
STUDY CRITERION
STUDY GUIDELINE
SUBSET
SYMPTOM
SYMPTOM
SYSTOLIC BLOOD PRESSURE
SYSTOLIC DYSFUNCTION
TACHYCARDIA
TACHYCARDIA
TAKE TIME
TIME-FROM-EVENT-TO-DEATH ANALYSIS
PARTICIPANT TIME-FROM-EVENT-TO-DEATH ANALYSIS
TOTAL DOSE
ADDED OPEN-LABEL DRUG TOTAL DOSE
TOTAL MORTALITY
TREATED HF
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TWO-COMPONENT
CLINICAL TRIAL TWO-COMPONENT
TWO-FOLD
INCREASED RELATIVE RISK TWO-FOLD
TWO-THIRDS
VALIDATION
VALIDATION
VALIDATION
VALIDATION EXERCISE
HF DIAGNOSIS VALIDATION
VENTRICULAR DYSFUNCTION
VENTRICULAR FUNCTION
VENTRICULAR HYPERTROPHY
VENTRICULAR HYPERTROPHY
VENTRICULAR SYSTOLIC FUNCTION
CORONARY HEART DISEASE
CHD
ANGIOTENSIN-CONVERTING ENZYME
ACE
CVD
SBP
HDL
BLOOD PRESSURE
BP
CHRONIC           OBSTRUCTIVE PULMONARY DISEASE
COPD
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
ASCVD
CORONARY ARTERY BYPASS GRAFTS
CABGS
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
ASCVD
LEFT VENTRICULAR           HYPERTROPHY
LVH
PULSE PRESSURE
PP
ATHEROSCLEROTIC         CARDIOVASCULAR DISEASE
ASCVD
ABBOTT
AB
AZ
BV
BRISTOL-MYERS SQUIBB
BMS
GLAXO-SMITHKLINE/SMITHKLINE BEECHAM
GSK/SKB
PHU
SY
SEARLE
SE
SV
MEDICAL/SCIENTIFIC STATEMENT
MANUAL
definitions
ALLHAT EVENT
INFORMATION
INFORMATION
INFORMATION
BASELINE
BASELINE
BASELINE
BASELINE
BASELINE
PULSE PRESSURE
uses
STATISTICS
DOXAZOSIN
FRACTION REVIEW
ENDPOINT
ascertainment
DIAGNOSIS
DIAGNOSIS
DIAGNOSIS
DIAGNOSIS
DIAGNOSIS
events
HF EVENT
HOSPITALIZATION
outcomes
outcomes
HF OUTCOME
HF OUTCOME
PARTICIPANT
HEART
ATTACK TRIAL
HEART
FAILURE
HEART FAILURE
HEART
FAILURE DIAGNOSIS
VI
PHARMACEUTICALS/MONARCH
TREATMENT
MEDICAL MANAGEMENT BASELINE
MEDICAL MANAGEMENT
BASELINE
HEART
HEART
YORK HEART CLASSIFICATION
HEART CLASSIFICATION
YORK HEART CLASSIFICATION
HEART CLASSIFICATION
OBJECTIVE
ASSESSMENT
EVENT MEDICAL MANAGEMENT
MEDICAL MANAGEMENT
PHARMACOLOGIC MANAGEMENT
pharmacologic
INVESTIGATOR
RISK
ST-T WAVE
REPORT
STUDY
GUIDELINES CAUTION
quality control
SYSTOLIC
TREATMENT
open-label drug
MORTALITY
MORTALITY
BLOCKER
PAIN
ENZYME (ACE)-INHIBITOR
EDEMA
ANTIHYPERTENSIVE
ANTIHYPERTENSIVE
TREATMENT
ANTIHYPERTENSIVE
trials
ASYMPTOMATIC
BASELINE
SBP
BASELINE
BASELINE
BASELINE
BASELINE
BASELINE ELIGIBILITY RISK
BASELINE
FASHION
MEDICATION
MEDICATION
quality control evaluation
CONTROL EVALUATION
REVIEW
BLOCKER
CARDIOVASCULAR RISK
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE TREATMENT
CHLORTHALIDONE
CHLORTHALIDONE TREATMENT
CHLORTHALIDONE
CHLORTHALIDONE TREATMENT
CHLORTHALIDONE
OBSTRUCTIVE PULMONARY DISEASE
COURSE
DIAGNOSIS
INVESTIGATOR
pictures
trials
INDICATION
reasons
CONFIRMATORY
EVENT DOCUMENTATION
CONFIRMATORY
EVIDENCE
CONSULTANT
CORONARY ARTERY
CORONARY ARTERY
coronary revascularization
revascularization
coronary revascularization
revascularization
coronary revascularization
revascularization
coronary revascularization
revascularization
CUMULATIVE EVENT
deaths
certificates
deaths
deaths
INFORMATION
DIASTOLIC
HF
DIASTOLIC
BLOOD PRESSURE
DIASTOLIC
dysfunction
DIASTOLIC
dysfunction
DISCHARGE
DISCHARGE
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN TREATMENT
DOXAZOSIN
DOXAZOSIN TREATMENT
DOXAZOSIN
drugs
drugs
drugs
drugs
drugs
FRACTION INFORMATION
EJECTION
EJECTION
EJECTION
EJECTION
EJECTION
ELIGIBILITY RISK
ELIGIBILITY RISK
ENCOMPASSING CHD
CHD
ENDPOINT
EVENT ASCERTAINMENT
events
ascertainment
events
DOCUMENTATION
events
DYSPNEA
INVESTIGATION SUPPORT
EDEMA
CHD
CHD
HF
HF
HF
HF
FATAL HF
HF
words
FOLLOW-UP
CLINIC VISIT
HEART
FAILURE
HEART
FAILURE
lipoprotein
HIGH-RISK HYPERTENSIVE
HYPERTENSIVE
DISCHARGE
HF
HF
HF
HOSPITALIZED HF
HF
HOSPITALIZED HF
HF
HOSPITALIZED HF
HF
HOSPITALIZED HF
HF
NONFATAL HF
NONFATAL
HOSPITALIZED NONFATAL HF
NONFATAL
HF
HF
HYPERCHOLESTEROLEMIC
CHD DEATH
CHD
CHD DEATH
CHD
NONINVASIVE
INCREASED HF
HF
occurrences
rr
HOSPITALIZATION
VENOUS DISTENTION
LIPID
trials
RISK FACTOR
limitations
maximum
PP
BASELINE PP
BASELINE
MEDICATION
ADHERENCE
ALLHAT
MENTIONED EJECTION
HG
HG
HG
HG
HG
HG
MORTALITY
NON-CARDIAC
NON-HOSPITALIZED
HF
NON-HOSPITALIZED
NONFATAL
NONFATAL
NONFATAL
NONFATAL
NONFATAL
NONFATAL
myocardial infarction
OBJECTIVE
increases
ordinary physical activity
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
ATHEROSCLEROTIC
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
ATHEROSCLEROTIC
RISK FACTOR
revascularization
revascularization
NOCTURNAL DYSPNEA
percutaneous
ARTERIAL DISEASE
ARTERIAL DISEASE
uses
differences
PRE-TRIAL ANTIHYPERTENSIVE TREATMENT
ANTIHYPERTENSIVE
ENDPOINT
ENDPOINT
ENDPOINT
ENDPOINT
DOCUMENTATION
quality control
CONTROL VALIDATION
systolic failure
SYSTOLIC
RANDOMIZATION
RANDOMIZATION
RANDOMIZATION
visits
HF
REPORTED HF
HF
REPORTED HF
HF
RESEARCH
REVIEWED DISCHARGE
ENDPOINT
ENDPOINT
ADHERENCE
benefits
SIDE
standards
STUDY
STUDY
STUDY
GUIDELINES
SYSTOLIC
BLOOD PRESSURE
SYSTOLIC
dysfunction
times
TOTAL
TOTAL
MORTALITY
HF
TREATMENT
TREATMENT
TREATMENT
TREATMENT
TREATMENT
TREATMENT
TREATMENT
TREATMENT
TREATMENT
VALIDATION
EXERCISE
dysfunction
functions
hypertrophy
hypertrophy
SYSTOLIC FUNCTION
SYSTOLIC
